Nepafenac

證據等級: L5

預測適應症: 10 個

Nepafenac: From Postoperative Ocular Inflammation to Eye Disease

One-Sentence Summary

Nepafenac is a topical ophthalmic NSAID prodrug whose established use is controlling inflammation and pain after cataract surgery (and preventing cystoid macular edema). The TxGNN model’s top prediction is the broad category “Eye Disease,” supported by 41 clinical trials and 20 publications — but as detailed below, this evidence largely reflects the drug’s already-approved use rather than a genuinely novel indication.

Quick Overview

Item	Content
Original Indication	Postoperative ocular inflammation and pain (cataract surgery), including CME prevention — inferred from trial evidence; official license text unavailable (data gap)
Predicted New Indication	Eye Disease (broad grouping)
TxGNN Prediction Score	99.85%
Evidence Level	L1
US Market Status	Not Marketed (per this evidence pack)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Nepafenac is a prodrug that, following topical ocular administration, is hydrolyzed intraocularly to its active metabolite amfenac, a non-selective COX-1/COX-2 inhibitor. This mechanism underlies its established anti-inflammatory and analgesic effect in the eye, particularly for controlling inflammation and pain after cataract surgery and reducing the risk of postoperative cystoid macular edema (CME).

The TxGNN model’s top-ranked prediction, “eye disease,” is mechanistically coherent — but the evidence pack itself flags an important caveat: this is a very broad disease grouping, and essentially all of the supporting clinical trials and literature relate to nepafenac’s existing, already-approved indication (postoperative ophthalmic inflammation/pain and CME prophylaxis), not a novel disease target. In other words, the model has high confidence largely because it is re-confirming known pharmacology rather than surfacing a new repurposing opportunity.

That said, within this broad “eye disease” evidence set are pockets of more exploratory signal — e.g., use in vitreoretinal inflammation following retinal detachment repair, uveitis-associated macular edema, and diabetic macular edema — that could warrant closer, disease-specific evaluation separate from the general “eye disease” label. Two related, disease-specific candidates from this run (optic papillitis, vitreous detachment) each returned only sparse or preclinical evidence and are scored as Hold/Research Question, underscoring that the strength here sits with the known indication, not adjacent ones.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01318499	Phase 2	Completed	1342	Large dose-comparison trial: nepafenac 0.3% vs 0.1% vs vehicle for prevention/treatment of ocular inflammation and pain after cataract surgery
NCT02084576	Phase 4	Completed	40	Prospective randomized double-masked comparison of ketorolac 0.4% vs nepafenac 0.1% for prevention of cystoid macular edema after phacoemulsification
NCT00818844	Phase 4	Completed	40	Topical nepafenac 0.1% vs placebo for reducing macular volume after epiretinal membrane surgery
NCT07162818	Phase 4	Completed	61	Effects of nepafenac 0.1% on vitreous inflammatory biomarkers in rhegmatogenous retinal detachment and proliferative vitreoretinopathy
NCT00347204	Phase 4	Completed	40	Double-masked comparison of Acular LS vs Nevanac (nepafenac) for postoperative pain control after PRK
NCT00348582	Phase 4	Completed	N/A	Acular LS vs Nevanac for postoperative inflammation following cataract surgery
NCT01475877	N/A	Completed	20	Bromfenac 0.09% QD vs Nevanac (nepafenac) 0.1% TID for pain control and epithelial healing after PRK
NCT00865540	Phase 4	Unknown	30	Comparison of prednisolone acetate 1%, nepafenac 0.1%, and ketorolac 0.4% for maintaining intraoperative mydriasis during phacoemulsification
NCT01939691	Phase 4	Terminated	9	Nepafenac vs difluprednate regimens for uveitis-associated macular edema
NCT05847049	N/A	Completed	16	Combined eplerenone, intravitreal aflibercept, and topical nepafenac for serous foveal detachment in central serous chorioretinopathy

41 clinical trials were identified in total against the “eye disease” query; the trials above are the 10 rated most relevant.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32672612	2020	RCT	Ophthalmology. Glaucoma	Nepafenac 0.1% vs prednisolone acetate 1% for controlling inflammation after laser peripheral iridotomy
35025078	2022	Review	Drugs	Review of diagnostic agents and therapeutic medications for non-infectious corneal injury
16466612	2006	Review	Curr Med Res Opin	Ocular permeation and inhibition of retinal inflammation — clinical utility of nepafenac
34120417	2021	Cohort	Korean J Ophthalmol	Nepafenac 0.1% vs prednisolone acetate 1% in postoperative management after micro-incisional cataract surgery
29199864	2018	Cohort	Curr Eye Res	Intracameral nepafenac safety and efficacy in inhibiting prostaglandin synthesis during phacoemulsification
30284393	2018	Cohort	Acta Ophthalmol	Nepafenac vs preservative-free diclofenac in postoperative management after cataract surgery
25493620	2016	Cohort	J Glaucoma	Interaction of nepafenac and prostaglandin analogs in primary open-angle glaucoma patients
26474497	2016	PK/Preclinical	Exp Eye Res	Distribution of topical nepafenac and active metabolite amfenac to the posterior segment of the eye
19897019	2010	Preclinical	Brain Res Bull	Effects of nepafenac and amfenac on retinal angiogenesis
24697218	2014	Preclinical	J Pharm Pharmacol	Effects of topical indomethacin, bromfenac and nepafenac on LPS-induced ocular inflammation

20 publications were identified in total against the “eye disease” query; the 10 above are prioritized by evidence tier (RCT > Review > Cohort > Preclinical).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Evidence strength is high (L1) with numerous completed Phase 2/3 RCTs, but this evidence chiefly validates nepafenac’s known approved use rather than a distinct new indication — “eye disease” is too broad a category to treat as a novel repurposing signal. Before any regulatory or clinical action, the blocking safety data gap must be resolved.

To proceed, the following is needed:

TFDA/FDA package insert data — warnings, precautions, and contraindications (currently missing; flagged as a Blocking data gap that prevents entry into the S1 safety review stage)
Confirmed mechanism-of-action documentation at the drug record level (currently a data gap; this report’s MOA discussion was reconstructed from trial/literature evidence, not a verified source record)
Re-scoping of the “eye disease” prediction into disease-specific sub-indications (e.g., uveitic macular edema, post-vitrectomy inflammation) to distinguish genuinely novel signal from confirmation of existing use
Verified US/Taiwan market authorization records, since this evidence pack shows zero licenses on file despite nepafenac’s known marketed ophthalmic products (Nevanac, Ilevro) — this is likely a data completeness gap that should be corrected before final decisioning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.